Alkylating antineoplastic agent: Class Overview and Comparison
Quick answer: Alkylating antineoplastic agent are a class of medicines used for specific therapeutic indications. iMedic covers 7 alkylating antineoplastic agent substances. Below is a comparison table linking to detailed pages for each.
Alkylating antineoplastic agent on iMedic (7 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Bendamustine | Chronic lymphocytic leukemia, Non-Hodgkin lymphoma | Bifunctional alkylating agent that cross-links DNA, inhibiting replication and i | 90-120 mg/m² IV on days 1-2 of 28-day cycle |
| Busulfan | Chronic myeloid leukemia, Conditioning before hematopoietic stem cell transplantation | Bifunctional alkylating agent that cross-links DNA strands | Oral 2-8 mg/day; IV 0.8 mg/kg every 6 hours for conditioning |
| Dacarbazine | Metastatic melanoma, Hodgkin lymphoma | Alkylating agent that methylates DNA causing strand breaks and inhibiting nuclei | 200-250 mg/m2 IV daily for 5 days every 3-4 weeks |
| Phelinun | Multiple myeloma conditioning regimen, Childhood acute leukemia conditioning before HSCT | Bifunctional alkylating agent that cross-links DNA inhibiting replication and tr | 100-200 mg/m² IV as conditioning before stem cell transplant |
| Thiotepa | Conditioning before hematopoietic stem cell transplantation, Breast cancer | Polyfunctional alkylating agent that crosslinks DNA inhibiting replication and i | 5-10 mg/kg IV (varies by indication and protocol) |
| Thiotepa Abcur | Conditioning before hematopoietic stem cell transplantation, Breast cancer | Polyfunctional alkylating agent that crosslinks DNA inhibiting replication and i | 5-10 mg/kg IV (varies by indication and protocol) |
| Tiotepa | Conditioning before hematopoietic stem cell transplantation, Bladder cancer | Polyfunctional alkylating agent that cross-links DNA inhibiting cell replication | Varies by indication; HSCT conditioning typically 5-10 mg/kg IV |
About Alkylating antineoplastic agent
Alkylating antineoplastic agent share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Alkylating antineoplastic agent?
Alkylating antineoplastic agent are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 7 substances in this class with detailed pages for each.
Are all Alkylating antineoplastic agent interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Alkylating antineoplastic agent?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Alkylating antineoplastic agent available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.